Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Jean-Luc Van Laethem, ASCO GI 2021: Pembrolizumab for Advanced Hepatocellular Carcinoma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Feb 23rd 2021

We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) around pembrolizumab therapy in patients with previously untreated advanced hepatocellular carcinoma (Clinical Trial Identifier: NCT02702414).

The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.

Questions

  1. What is the current status of pembrolizumab in the treatment of patients with advanced hepatocellular carcinoma (HCC), and how will the findings of KEYNOTE-224 impact on future research? (0:39)
  2. Which patients are most likely to respond to pembrolizumab therapy? (2:35)

Disclosures: Jean-Luc Van Laethem has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of ASCO GI 2021 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup